Running a peptide company puts more than products at risk—it puts the people at the top in the crosshairs. D&O insurance protects executives, board members, and founders from personal financial liability in the heavily scrutinized peptide industry.
Dean Hamid, CLCS, AINS
PRIA Brokers — Peptide Insurance Specialist
Most peptide company owners think about product liability, general liability, or E&O coverage. What they rarely plan for is the moment a regulator, investor, or plaintiff doesn't sue the company—they sue *you*.
Directors & Officers (D&O) insurance is designed for exactly that scenario. It covers the personal financial exposure of executives, founders, board members, and managers when decisions made in their leadership capacity are challenged in court, by a government agency, or by shareholders.
In the peptide industry—where FDA enforcement, FTC scrutiny, and investor disputes are increasingly common—D&O coverage is no longer optional for any company with serious leadership.
D&O policies have three coverage parts, often called Side A, Side B, and Side C:
This is the most critical piece. If your company is insolvent, bankrupt, or legally prohibited from covering your defense costs, Side A pays directly to you as an individual. Without it, your personal assets—savings, home, retirement accounts—are exposed.
When the company does indemnify a director or officer (pays their defense costs), Side B reimburses the company. This protects company cash flow during litigation.
For companies with outside investors, Side C covers the entity itself when securities claims are filed alongside D&O claims. This is particularly relevant for peptide startups and growth-stage companies that have taken on venture or angel investment.
The peptide industry sits at an unusually high-risk intersection of healthcare, pharmaceuticals, regulatory compliance, and entrepreneurship. Here's why that makes D&O claims more likely:
The FDA's enforcement posture toward compounding pharmacies, peptide manufacturers, and GLP-1 distributors has intensified since 2023. Warning letters, injunctions, and consent decrees frequently name individuals—not just companies. Executives who signed off on production decisions, marketing claims, or distribution agreements can be held personally liable.
D&O coverage can fund your defense even when the underlying action is regulatory rather than civil.
The GLP-1 boom attracted significant capital into the peptide space. When business outcomes don't match projections—or when a company pivots, loses a key contract, or faces a regulatory setback—investors may claim breach of fiduciary duty, misrepresentation, or negligent management. These claims go directly to leadership.
D&O insurance responds to these investor-driven claims. Without it, a founder defending against a well-funded investor lawsuit faces catastrophic personal exposure.
The FTC has been aggressive in pursuing companies that make unsubstantiated health and efficacy claims. When enforcement reaches the executive level—as it often does in industries making borderline therapeutic claims—the individuals who approved marketing materials can be named personally.
Rapid growth in the peptide sector has led to aggressive hiring and, inevitably, difficult terminations. Claims of wrongful termination, discrimination, hostile work environment, or retaliation are common in fast-growing companies. While EPLI (Employment Practices Liability Insurance) is the primary vehicle for these claims, D&O policies can overlap when the alleged decisions trace back to executive leadership.
Peptide companies often operate in complex supply chains—API suppliers, contract manufacturers, distributors, and healthcare providers. When a business decision harms a supply chain partner (e.g., a sudden termination of agreement, a pricing dispute, or an allocation decision during shortage), breach of contract and tortious interference claims can follow—and they can name the individual who made the call.
If you hold any of the following roles at a peptide company, you need to understand your D&O exposure:
**Founders and co-founders** — personally exposed on virtually every business decision the company has made
**CEOs, COOs, CFOs** — named in regulatory and investor actions as the responsible parties
**Board members and advisors** — even outside directors face liability for decisions made in board meetings
**Vice Presidents and department heads** — in smaller companies, operational leaders often have "officer" status and exposure to match
**Private equity and venture investors on the board** — sitting on a portfolio company's board creates D&O exposure for your firm
If your peptide company has employees, investors, suppliers, or regulatory obligations—and every operating company does—D&O exposure exists.
Your compounding pharmacy receives an FDA Warning Letter citing improper manufacturing practices. The letter names you as the Responsible Official. The agency opens an investigation. Your legal defense alone could cost $150,000 to $500,000. D&O coverage funds that defense.
Post-FDA ruling, you make the decision to pivot your business away from compounded GLP-1 products. An early investor argues you didn't disclose the regulatory risk at the time of investment and sues for breach of fiduciary duty. D&O responds.
You signed a multi-year manufacturing agreement and then exited it early after finding a better-priced supplier. The contract manufacturer sues you personally, claiming you never intended to honor the full term. D&O provides defense coverage.
You terminate your VP of Operations after discovering compliance issues. She counters with a wrongful termination and retaliation suit, alleging the compliance concerns were pretextual. The suit names you personally as the decision-maker. D&O responds.
Understanding exclusions is just as important as understanding what's covered. Standard D&O policies will not cover:
**Intentional fraud or criminal acts** — if a court finds you committed intentional wrongdoing, coverage typically voids
**Personal profit obtained illegally** — clawback of improperly gained compensation is excluded
**Bodily injury and property damage** — these belong in GL and product liability policies
**Prior known claims** — D&O is claims-made; acts you knew about before the policy started are excluded
**Certain regulatory penalties** — some fines and penalties are uninsurable as a matter of public policy
This is why working with a broker who understands peptide industry exposures—not just generic D&O—matters. Policy language and exclusion carve-backs vary significantly.
There's no single right answer, but here are common benchmarks by company stage:
**Early-stage startup (pre-revenue):** $1M–$2M limit is typically a baseline starting point.
**Growth-stage with outside investors:** $3M–$5M is more appropriate as investor exposure and operational complexity increase.
**Established manufacturer or distributor:** $5M–$10M for companies with meaningful revenue, regulatory footprint, and supply chain relationships.
**Multi-entity or complex organizational structures:** $10M+ for holding companies, multi-state operations, or businesses with significant FDA oversight.
In the peptide industry, FDA and FTC investigations can generate defense costs that dwarf what more conventional businesses face. We generally recommend erring toward higher limits for any company with regulatory exposure or outside investors.
D&O doesn't exist in isolation. For a peptide company to be properly protected, it should work alongside:
**Product Liability Insurance** — for claims arising from the peptides themselves
**General Liability Insurance** — for premises and operational risk
**E&O / Professional Liability** — for claims arising from professional services and advice
**Product Recall Insurance** — for the costs of pulling products from distribution
**FDA/FTC Regulatory Defense Insurance** — for government investigations at the entity level
**Cyber Liability Insurance** — for data breach and ransomware exposure, especially relevant for telehealth platforms
A well-structured program layers these coverages so that any claim—whether against the company or against the individuals running it—has a responsive policy.
The peptide industry is high-growth, high-scrutiny, and high-stakes. That combination creates personal liability exposure for every person in a leadership role. D&O insurance isn't a luxury reserved for large corporations—it's essential protection for any founder, executive, or board member whose decisions could face challenge from regulators, investors, employees, or business partners.
If you're running a peptide company without D&O coverage, you're personally exposed in ways that could follow you long after the company itself is gone.
PRIA Brokers specializes in insurance programs built specifically for the peptide industry. We understand the regulatory environment, the risk profile, and the coverage structures that actually respond when claims happen.
**Contact us at (888) 998-7742 or info@priabrokers.com to discuss D&O coverage for your company.**
PRIA Brokers specializes in coverage for peptide manufacturers, GLP-1 compounders, distributors, and suppliers. Compare quotes from A-rated specialty carriers.